Ser811
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser811  -  Rb (human)

Site Information
IyIsPLksPykIsEG   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448717
Available spectra:  3 CST

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 145 , 146 , 147 ) , electrophoretic mobility shift ( 114 , 145 , 146 ) , immunoprecipitation ( 1 , 7 ) , mass spectrometry ( 1 , 2 , 4 , 6 , 9 , 14 , 15 , 17 , 18 , 19 , 20 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 30 , 32 , 33 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 43 , 44 , 45 , 46 , 47 , 51 , 52 , 53 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 91 , 92 , 94 , 95 , 96 , 97 , 98 , 99 , 101 , 102 , 103 , 104 , 105 , 106 , 108 , 109 , 110 , 111 , 112 , 113 , 120 , 121 , 122 , 123 , 124 , 125 , 127 , 128 , 129 , 130 , 136 , 147 ) , mass spectrometry (in vitro) ( 65 ) , microscopy-colocalization with upstream kinase ( 144 ) , modification-specific antibody ( 7 ) , mutation of modification site ( 1 , 31 , 141 , 145 , 146 ) , phospho-antibody ( 1 , 5 , 7 , 8 , 10 , 11 , 13 , 42 , 48 , 49 , 50 , 54 , 90 , 93 , 100 , 107 , 114 , 115 , 117 , 118 , 119 , 126 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 140 , 141 , 144 , 148 ) , phosphopeptide mapping ( 147 ) , western blotting ( 1 , 5 , 8 , 10 , 11 , 13 , 31 , 42 , 48 , 49 , 50 , 54 , 90 , 93 , 100 , 107 , 114 , 115 , 117 , 133 , 135 , 137 , 138 , 148 )
Disease tissue studied:
bone cancer ( 8 , 146 ) , brain cancer ( 10 , 50 , 54 ) , glioblastoma ( 10 , 50 , 54 ) , glioma ( 10 , 50 , 54 ) , breast cancer ( 4 , 5 , 15 , 17 , 32 , 42 ) , breast ductal carcinoma ( 15 ) , HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, surrounding tissue ( 2 ) , breast cancer, triple negative ( 2 ) , cervical cancer ( 31 , 76 , 145 , 146 ) , cervical adenocarcinoma ( 76 ) , colorectal cancer ( 1 , 13 , 93 ) , colorectal carcinoma ( 1 , 13 , 93 ) , eye cancer ( 144 ) , intraocular melanoma ( 144 ) , leukemia ( 35 , 77 , 78 , 92 , 127 , 128 , 129 , 130 , 147 ) , acute myelogenous leukemia ( 35 , 147 ) , chronic myelogenous leukemia ( 77 , 78 , 92 , 127 , 128 , 129 , 130 ) , lung cancer ( 13 , 22 , 23 , 24 , 25 , 26 , 27 , 32 , 56 ) , non-small cell lung cancer ( 13 , 22 , 23 , 24 , 26 , 27 , 32 ) , non-small cell lung adenocarcinoma ( 13 , 22 , 23 , 24 , 25 , 26 , 27 ) , non-small cell large cell lung carcinoma ( 23 , 26 ) , non-small cell squamous cell lung carcinoma ( 25 ) , lymphoma ( 19 , 115 ) , Burkitt's lymphoma ( 19 , 115 ) , follicular lymphoma ( 19 ) , mantle cell lymphoma ( 19 ) , prostate cancer ( 5 , 114 , 137 , 148 ) , melanoma skin cancer ( 9 , 126 ) , rhabdomyosarcoma ( 107 )
Relevant cell line - cell type - tissue:
'eye, retinal pigmented epithelium' ( 144 ) , 'hematopoietic progenitor, CD34+' ( 119 ) , 'muscle, smooth' ( 100 ) , 'stem, hematopoietic' ( 11 ) , 293 (epithelial) ( 7 , 18 ) , 293 (epithelial) [5-HT(2A) (human), transfection] ( 18 ) , 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 62 ) , 293T (epithelial) ( 7 ) , 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout] ( 136 ) , 786-O (renal) ( 6 ) , 786-O (renal) [VHL (human), transfection] ( 6 ) , A2780 (ovarian) ( 134 ) , A549 (pulmonary) ( 13 , 22 ) , BJAB (B lymphocyte) ( 19 ) , breast ( 2 , 15 ) , BT-20 (breast cell) ( 32 ) , BT-474 (breast cell) ( 4 ) , BT-549 (breast cell) ( 32 ) , C2C12 (myoblast) ( 117 ) , C2C12 (myoblast) [SPRY2 (human), transfection] ( 117 ) , C33-A (cervical) ( 31 , 145 , 146 ) , Cal-12T (pulmonary) ( 27 ) , Calu 6 (pulmonary) ( 32 ) , Calu-3 (pulmonary) ( 24 ) , CCD-18Co ( 133 ) , CL1-0 (pulmonary) ( 56 ) , CL1-1 (pulmonary) ( 56 ) , CL1-2 (pulmonary) ( 56 ) , CL1-5 (pulmonary) ( 56 ) , COS (fibroblast) ( 146 ) , DG75 (B lymphocyte) ( 58 ) , DLD1 (intestinal) ( 1 ) , DMS53 (pulmonary) ( 120 ) , DU 145 (prostate cell) ( 137 ) , FL-18 (B lymphocyte) ( 19 ) , FL-318 (B lymphocyte) ( 19 ) , Flp-In T-Rex-293 (epithelial) ( 33 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 33 ) , GM00130 (B lymphocyte) ( 63 ) , GM00637 (fibroblast) ( 132 ) , H2009 (pulmonary) ( 32 , 90 ) , H2077 (pulmonary) ( 32 ) , H2887 (pulmonary) ( 32 ) , H322 (pulmonary) ( 32 ) , H322M (pulmonary) ( 32 ) , HaCaT (keratinocyte) ( 138 ) , HCC15 (pulmonary) ( 25 ) , HCC1937 (breast cell) ( 32 ) , HCC2279 (pulmonary) ( 32 ) , HCC366 (pulmonary) ( 32 ) , HCC44 (pulmonary) ( 27 ) , HCC78 (pulmonary) ( 26 , 32 ) , HCC827 (pulmonary) ( 24 ) , HCT116 (intestinal) ( 1 ) , HEL (erythroid) ( 112 , 113 ) , HeLa (cervical) ( 14 , 30 , 57 , 59 , 82 , 89 ) , HeLa S3 (cervical) ( 76 ) , HFFF-2 (fibroblast) ( 145 ) , HMLER ('stem, breast cancer') ( 17 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 17 ) , HOP62 (pulmonary) ( 32 ) , HT-29 (intestinal) ( 13 , 121 , 122 , 123 , 124 , 125 ) , HUES-9 ('stem, embryonic') ( 53 ) , IMR-90 (fibroblast) ( 1 , 48 ) , JB (epithelial) ( 135 ) , JEKO-1 (B lymphocyte) ( 19 ) , Jurkat (T lymphocyte) ( 28 , 36 , 37 , 38 , 39 , 40 , 41 , 43 , 44 , 45 , 46 , 47 , 51 , 52 , 55 , 60 , 61 , 64 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 80 , 81 , 83 , 84 , 85 , 88 , 91 , 94 , 95 , 96 , 97 , 98 , 99 ) , K562 (erythroid) ( 30 , 77 , 78 , 79 , 92 , 127 , 128 , 129 , 130 ) , KG-1 (myeloid) ( 35 ) , Kyse140 (esophageal) ( 103 , 104 ) , LAN-1 (neural crest) ( 118 ) , LN229 (glial) ( 10 ) , LNCaP (prostate cell) ( 5 , 114 , 148 ) , LOU-NH91 (squamous) ( 25 , 32 ) , lung ( 22 , 23 , 24 , 25 , 26 , 27 ) , MCF-7 (breast cell) ( 4 , 32 , 42 , 140 ) , MDA-MB-231 (breast cell) ( 5 , 32 ) , MDA-MB-468 (breast cell) ( 32 ) , MEF (fibroblast) [IGF1R (mouse)] ( 141 ) , melanocyte-skin ( 126 ) , MKN-45 (gastric) ( 86 , 87 ) , ML-1 (myeloid) ( 147 ) , Molm 14 (myeloid) ( 101 , 102 ) , mononuclear ( 119 ) , muscle ( 107 ) , MV4-11 (macrophage) ( 105 , 106 ) , NCEB-1 (B lymphocyte) ( 19 ) , NCI-H1299 (pulmonary) ( 23 ) , NCI-H1355 (pulmonary) ( 22 ) , NCI-H1395 (pulmonary) ( 32 ) , NCI-H1437 (pulmonary) ( 27 ) , NCI-H1568 (pulmonary) ( 32 ) , NCI-H157 (pulmonary) ( 32 ) , NCI-H1648 (pulmonary) ( 32 ) , NCI-H1650 (pulmonary) ( 24 ) , NCI-H1666 (pulmonary) ( 27 , 32 ) , NCI-H1703 (squamous) ( 25 ) , NCI-H1734 (pulmonary) ( 23 ) , NCI-H1781 (pulmonary) ( 26 ) , NCI-H1792 (pulmonary) ( 22 ) , NCI-H1944 (pulmonary) ( 23 ) , NCI-H1975 (pulmonary) ( 24 ) , NCI-H2030 (pulmonary) ( 32 ) , NCI-H2073 (pulmonary) ( 25 ) , NCI-H2106 (pulmonary) ( 24 ) , NCI-H2172 (pulmonary) ( 32 ) , NCI-H2228 (pulmonary) ( 26 ) , NCI-H23 (pulmonary) ( 22 ) , NCI-H2342 (pulmonary) ( 25 ) , NCI-H2405 (pulmonary) ( 27 ) , NCI-H3122 (pulmonary) ( 26 ) , NCI-H358 (pulmonary) ( 23 ) , NCI-H441 (pulmonary) ( 22 ) , NCI-H460 (pulmonary) ( 23 , 32 ) , NCI-H647 (pulmonary) ( 32 ) , NCI-H661 (pulmonary) ( 26 ) , NMB (neuron) ( 118 ) , OCI-ly1 (B lymphocyte) ( 19 ) , OVCAR3 (ovarian) ( 134 ) , PC3 (prostate cell) ( 114 , 137 ) , Raji (B lymphocyte) ( 19 ) , RAMOS (B lymphocyte) ( 19 , 115 ) , Rat1 (fibroblast) ( 145 ) , Rat2 (fibroblast) ( 141 ) , REC-1 (B lymphocyte) ( 19 ) , Rh30 (muscle cell) ( 107 ) , RPE-1 (epithelial) ( 49 ) , Saos-2 (bone cell) ( 8 , 136 , 140 , 146 ) , SEM (B lymphocyte) ( 108 , 109 , 110 , 111 ) , SH-SY5Y (neural crest) ( 20 ) , SU-DHL-4 (B lymphocyte) ( 19 , 132 ) , SU-DHL-6 (B lymphocyte) ( 132 ) , SU-DHL-9 (B lymphocyte) ( 132 ) , SW480 (intestinal) ( 93 ) , U-937 (myeloid) ( 139 ) , U2OS (bone cell) [GR (human)] ( 141 ) , U87MG (glial) ( 10 , 50 , 54 ) , WI-38 (fibroblast) ( 7 ) , WM239A (epidermal) ( 9 )

Upstream Regulation
Regulatory protein:
Akt1 (human) ( 1 , 48 ) , Bcl-2 (human) ( 132 ) , CCNE1 (human) ( 90 ) , DYNLT1 (human) ( 49 ) , HRas (human) ( 1 , 48 ) , JMJD3 (human) ( 7 ) , KAP (mouse) ( 10 ) , MLK3 (human) ( 133 ) , NOX4 (human) ( 100 ) , p57Kip2 (human) ( 107 ) , p73 (human) ( 107 ) , PPP1R1C (human) ( 93 ) , VHL (human) ( 6 )
Putative in vivo kinases:
CDK3 (human) ( 136 ) , UL97 (herpesvirus) ( 8 )
Kinases, in vitro:
CDK1 (human) ( 147 ) , CDK2 (human) ( 146 ) , CDK4 (human) ( 143 , 148 ) , CDK5 (human) ( 131 ) , CDK6 (human) ( 116 ) , CDK9 (human) ( 142 )
Treatments:
3-Methyladenine ( 54 ) , anti-CD3 ( 85 ) , Bz-423 ( 115 ) , caffeine ( 50 , 135 ) , catalase ( 100 ) , DOI ( 18 ) , eflornithine ( 118 ) , estradiol ( 140 ) , eusynstyelamide B ( 5 ) , faslodex ( 140 ) , FGF2 ( 117 ) , fluvastatin ( 114 ) , insulin ( 117 ) , IP(6) ( 148 ) , ischemia ( 15 ) , lovastatin ( 114 ) , LRRK2-IN-1 ( 20 ) , LY294002 ( 134 , 137 ) , metastatic potential ( 56 ) , mevastatin ( 114 ) , phytohemagglutinin ( 119 ) , pravastatin ( 114 ) , psoralen ( 138 ) , rapamycin ( 134 , 137 ) , resibufogenin ( 13 ) , resveratrol ( 54 ) , retinoic_acid ( 42 , 139 ) , sardomozide ( 118 ) , serum ( 49 , 117 , 133 , 134 , 137 , 138 ) , simvastatin ( 114 ) , siRNA ( 93 , 107 , 133 ) , TGF-beta ( 100 ) , UV ( 138 ) , Y27632 ( 10 )

Downstream Regulation
Effects of modification on Rb:
molecular association, regulation ( 132 , 145 , 146 ) , phosphorylation ( 7 )
Effects of modification on biological processes:
cell cycle regulation ( 118 , 134 ) , cell growth, altered ( 145 , 146 ) , transcription, altered ( 144 )
Inhibit interaction with:
Abl iso2 (human) ( 146 ) , E2F1 (human) ( 132 , 145 )

Disease / Diagnostics Relevance
Relevant diseases:
intraocular melanoma ( 144 ) , melanoma skin cancer ( 126 )

References 

1

Piscitello D, et al. (2018) AKT overactivation can suppress DNA repair via p70S6 kinase-dependent downregulation of MRE11. Oncogene 37, 427-438
28967905   Curated Info

2

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

3

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

4

Carrier M, et al. (2016) Phosphoproteome and Transcriptome of RA-Responsive and RA-Resistant Breast Cancer Cell Lines. PLoS One 11, e0157290
27362937   Curated Info

5

Liberio MS, et al. (2015) The ascidian natural product eusynstyelamide B is a novel topoisomerase II poison that induces DNA damage and growth arrest in prostate and breast cancer cells. Oncotarget 6, 43944-63
26733491   Curated Info

6

Malec V, Coulson JM, Urbé S, Clague MJ (2015) Combined Analyses of the VHL and Hypoxia Signaling Axes in an Isogenic Pairing of Renal Clear Cell Carcinoma Cells. J Proteome Res 14, 5263-72
26506913   Curated Info

7

Zhao L, et al. (2015) JMJD3 promotes SAHF formation in senescent WI38 cells by triggering an interplay between demethylation and phosphorylation of RB protein. Cell Death Differ 22, 1630-40
25698448   Curated Info

8

Iwahori S, Hakki M, Chou S, Kalejta RF (2015) Molecular Determinants for the Inactivation of the Retinoblastoma Tumor Suppressor by the Viral Cyclin-dependent Kinase UL97. J Biol Chem 290, 19666-80
26100623   Curated Info

9

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

10

Li H, et al. (2015) KAP regulates ROCK2 and Cdk2 in an RNA-activated glioblastoma invasion pathway. Oncogene 34, 1432-41
24704824   Curated Info

11

Laurenti E, et al. (2015) CDK6 Levels Regulate Quiescence Exit in Human Hematopoietic Stem Cells. Cell Stem Cell 16, 302-13
25704240   Curated Info

12

Kim KY, et al. (2015) PRMT4-Mediated Arginine Methylation Negatively Regulates Retinoblastoma Tumor Suppressor Protein and Promotes E2F-1 Dissociation. Mol Cell Biol 35, 238-48
25348716   Curated Info

13

Ichikawa M, et al. (2015) Resibufogenin Induces G1-Phase Arrest through the Proteasomal Degradation of Cyclin D1 in Human Malignant Tumor Cells. PLoS One 10, e0129851
26121043   Curated Info

14

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

15

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

16

Matsuda S, et al. (2014) PCTAIRE kinase 3/cyclin-dependent kinase 18 is activated through association with cyclin A and/or phosphorylation by protein kinase A. J Biol Chem 289, 18387-400
24831015   Curated Info

17

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

18

Karaki S, et al. (2014) Quantitative phosphoproteomics unravels biased phosphorylation of serotonin 2A receptor at Ser280 by hallucinogenic versus nonhallucinogenic agonists. Mol Cell Proteomics 13, 1273-85
24637012   Curated Info

19

Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42
24667141   Curated Info

20

Luerman GC, et al. (2014) Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J Neurochem 128, 561-76
24117733   Curated Info

21

Hattori T, et al. (2014) Distinct and site-specific phosphorylation of the retinoblastoma protein at serine 612 in differentiated cells. PLoS One 9, e86709
24466208   Curated Info

22

Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

23

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

24

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

25

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

26

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

27

Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

28

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

29

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

30

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

31

Lentine B, et al. (2012) Dephosphorylation of threonine-821 of the retinoblastoma tumor suppressor protein (Rb) is required for apoptosis induced by UV and Cdk inhibition. Cell Cycle 11, 3324-30
22895174   Curated Info

32

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

33

Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70
22496350   Curated Info

34

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

35

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

36

Guo A (2011) CST Curation Set: 12740; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

37

Guo A (2011) CST Curation Set: 12435; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

38

Guo A (2011) CST Curation Set: 12436; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

39

Guo A (2011) CST Curation Set: 12438; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981
Curated Info

40

Zhou J (2011) CST Curation Set: 12319; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

41

Guo A (2011) CST Curation Set: 12039; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

42

Clarke CJ, et al. (2011) Neutral sphingomyelinase-2 mediates growth arrest by retinoic acid through modulation of ribosomal S6 kinase. J Biol Chem 286, 21565-76
21536668   Curated Info

43

Guo A (2011) CST Curation Set: 12065; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

44

Guo A (2011) CST Curation Set: 12067; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

45

Guo A (2011) CST Curation Set: 12068; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981
Curated Info

46

Guo A (2011) CST Curation Set: 11986; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP
Curated Info

47

Guo A (2011) CST Curation Set: 11987; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XP
Curated Info

48

Kennedy AL, et al. (2011) Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. Mol Cell 42, 36-49
21474066   Curated Info

49

Li A, et al. (2011) Ciliary transition zone activation of phosphorylated Tctex-1 controls ciliary resorption, S-phase entry and fate of neural progenitors. Nat Cell Biol 13, 402-11
21394082   Curated Info

50

Ku BM, et al. (2011) Caffeine inhibits cell proliferation and regulates PKA/GSK3β pathways in U87MG human glioma cells. Mol Cells 31, 275-9
21229324   Curated Info

51

Guo A (2011) CST Curation Set: 11424; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

52

Guo A (2011) CST Curation Set: 11425; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

53

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

54

Filippi-Chiela EC, Villodre ES, Zamin LL, Lenz G (2011) Autophagy interplay with apoptosis and cell cycle regulation in the growth inhibiting effect of resveratrol in glioma cells. PLoS One 6, e20849
21695150   Curated Info

55

Possemato A (2010) CST Curation Set: 10875; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

56

Wang YT, et al. (2010) An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-97
20815410   Curated Info

57

Zhou J (2010) CST Curation Set: 10709; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

58

Iliuk AB, et al. (2010) In-depth analyses of kinase-dependent tyrosine phosphoproteomes based on metal ion-functionalized soluble nanopolymers. Mol Cell Proteomics 9, 2162-72
20562096   Curated Info

59

Zhou J (2010) CST Curation Set: 10685; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

60

Possemato A (2010) CST Curation Set: 10055; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

61

Possemato A (2010) CST Curation Set: 10054; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

62

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

63

Bennetzen MV, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9, 1314-23
20164059   Curated Info

64

Possemato A (2010) CST Curation Set: 9791; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP
Curated Info

65

Burke JR, Deshong AJ, Pelton JG, Rubin SM (2010) Phosphorylation-induced conformational changes in the retinoblastoma protein inhibit E2F transactivation domain binding. J Biol Chem 285, 16286-93
20223825   Curated Info

66

Possemato A (2010) CST Curation Set: 9695; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: YXp[ST]
Curated Info

67

Possemato A (2010) CST Curation Set: 9696; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: YXp[ST]
Curated Info

68

Possemato A (2010) CST Curation Set: 9639; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSPX(I/L/M/V)
Curated Info

69

Possemato A (2010) CST Curation Set: 9642; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSPX(I/L/M/V)
Curated Info

70

Possemato A (2010) CST Curation Set: 9284; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

71

Possemato A (2010) CST Curation Set: 9285; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

72

Guo A (2010) CST Curation Set: 9180; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

73

Possemato A (2010) CST Curation Set: 9048; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

74

Possemato A (2010) CST Curation Set: 9044; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

75

Possemato A (2010) CST Curation Set: 9036; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

76

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

77

Moritz A (2009) CST Curation Set: 8719; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

78

Moritz A (2009) CST Curation Set: 8720; Year: 2009; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

79

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

80

Possemato A (2009) CST Curation Set: 8362; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

81

Possemato A (2009) CST Curation Set: 6371; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP
Curated Info

82

Chen RQ, et al. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 69, 2663-8
19276368   Curated Info

83

Possemato A (2009) CST Curation Set: 6369; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP
Curated Info

84

Possemato A (2009) CST Curation Set: 6352; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981
Curated Info

85

Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46
19690332   Curated Info

86

Guo A (2008) CST Curation Set: 5570; Year: 2008; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981
Curated Info

87

Guo A (2008) CST Curation Set: 5571; Year: 2008; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981
Curated Info

88

Possemato A (2008) CST Curation Set: 5276; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

89

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

90

Park Y, et al. (2008) Low-penetrant RB allele in small-cell cancer shows geldanamycin instability and discordant expression with mutant ras. Cell Cycle 7, 2384-91
18677112   Curated Info

91

Zhou J (2008) CST Curation Set: 4704; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981
Curated Info

92

Stokes M (2008) CST Curation Set: 4391; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

93

Wang X, et al. (2008) IPP5, a novel protein inhibitor of protein phosphatase 1, promotes G1/S progression in a Thr-40-dependent manner. J Biol Chem 283, 12076-84
18310074   Curated Info

94

Possemato A (2008) CST Curation Set: 4344; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981
Curated Info

95

Possemato A (2008) CST Curation Set: 4345; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381
Curated Info

96

Possemato A (2008) CST Curation Set: 4346; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381
Curated Info

97

Possemato A (2008) CST Curation Set: 4347; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381
Curated Info

98

Stokes M (2008) CST Curation Set: 3884; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

99

Zhou J (2008) CST Curation Set: 3678; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981
Curated Info

100

Sturrock A, et al. (2007) Nox4 mediates TGF-beta1-induced retinoblastoma protein phosphorylation, proliferation, and hypertrophy in human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 292, L1543-55
17369289   Curated Info

101

Moritz A (2006) CST Curation Set: 1922; Year: 2006; Biosample/Treatment: cell line, Molm 14/Flt3 inhibitor; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

102

Moritz A (2006) CST Curation Set: 1924; Year: 2006; Biosample/Treatment: cell line, Molm 14/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

103

Yu J (2006) CST Curation Set: 1914; Year: 2006; Biosample/Treatment: cell line, Kyse140/serum starved; Disease: esophageal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

104

Yu J (2006) CST Curation Set: 1915; Year: 2006; Biosample/Treatment: cell line, Kyse140/serum starved; Disease: esophageal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

105

Moritz A (2006) CST Curation Set: 1897; Year: 2006; Biosample/Treatment: cell line, MV4-11/Flt3 inhibitor; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

106

Moritz A (2006) CST Curation Set: 1899; Year: 2006; Biosample/Treatment: cell line, MV4-11/-; Disease: acute myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

107

Cam H, et al. (2006) p53 family members in myogenic differentiation and rhabdomyosarcoma development. Cancer Cell 10, 281-93
17045206   Curated Info

108

Moritz A (2006) CST Curation Set: 1833; Year: 2006; Biosample/Treatment: cell line, SEM/Flt3 inhibitor; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

109

Moritz A (2006) CST Curation Set: 1835; Year: 2006; Biosample/Treatment: cell line, SEM/-; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

110

Moritz A (2006) CST Curation Set: 1825; Year: 2006; Biosample/Treatment: cell line, SEM/-; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

111

Moritz A (2006) CST Curation Set: 1823; Year: 2006; Biosample/Treatment: cell line, SEM/Flt3 inhibitor; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

112

Moritz A (2006) CST Curation Set: 1784; Year: 2006; Biosample/Treatment: cell line, HEL/Flt3 inhibitor; Disease: erythroid leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

113

Moritz A (2006) CST Curation Set: 1786; Year: 2006; Biosample/Treatment: cell line, HEL/-; Disease: erythroid leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

114

Sivaprasad U, Abbas T, Dutta A (2006) Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells. Mol Cancer Ther 5, 2310-6
16985065   Curated Info

115

Sundberg TB, et al. (2006) The immunomodulatory benzodiazepine Bz-423 inhibits B-cell proliferation by targeting c-myc protein for rapid and specific degradation. Cancer Res 66, 1775-82
16452238   Curated Info

116

Rubin SM, Gall AL, Zheng N, Pavletich NP (2005) Structure of the Rb C-terminal domain bound to E2F1-DP1: a mechanism for phosphorylation-induced E2F release. Cell 123, 1093-106
16360038   Curated Info

117

de Alvaro C, Martinez N, Rojas JM, Lorenzo M (2005) Sprouty-2 overexpression in C2C12 cells confers myogenic differentiation properties in the presence of FGF2. Mol Biol Cell 16, 4454-61
16000370   Curated Info

118

Wallick CJ, et al. (2005) Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells. Oncogene 24, 5606-18
16007177   Curated Info

119

Leibundgut K, Schmitz NM, Hirt A (2005) Catalytic activities of G1 cyclin-dependent kinases and phosphorylation of retinoblastoma protein in mobilized peripheral blood CD34+ hematopoietic progenitor cells. Stem Cells 23, 1002-11
15941859   Curated Info

120

Farnsworth C (2005) CST Curation Set: 759; Year: 2005; Biosample/Treatment: cell line, DMS53/serum starved; Disease: small-cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

121

Moritz A (2005) CST Curation Set: 801; Year: 2005; Biosample/Treatment: cell line, HT-29/-; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

122

Moritz A (2005) CST Curation Set: 662; Year: 2005; Biosample/Treatment: cell line, HT-29/-; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

123

Moritz A (2005) CST Curation Set: 663; Year: 2005; Biosample/Treatment: cell line, HT-29/-; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

124

Moritz A (2005) CST Curation Set: 664; Year: 2005; Biosample/Treatment: cell line, HT-29/-; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

125

Moritz A (2005) CST Curation Set: 665; Year: 2005; Biosample/Treatment: cell line, HT-29/-; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

126

Roesch A, et al. (2005) Overexpression and hyperphosphorylation of retinoblastoma protein in the progression of malignant melanoma. Mod Pathol 18, 565-72
15502804   Curated Info

127

Moritz A (2005) CST Curation Set: 587; Year: 2005; Biosample/Treatment: cell line, K562/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

128

Moritz A (2005) CST Curation Set: 588; Year: 2005; Biosample/Treatment: cell line, K562/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

129

Moritz A (2005) CST Curation Set: 589; Year: 2005; Biosample/Treatment: cell line, K562/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

130

Moritz A (2005) CST Curation Set: 590; Year: 2005; Biosample/Treatment: cell line, K562/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

131

Hamdane M, et al. (2005) p25/Cdk5-mediated retinoblastoma phosphorylation is an early event in neuronal cell death. J Cell Sci 118, 1291-8
15741232   Curated Info

132

Youn CK, et al. (2005) Bcl-2 expression suppresses mismatch repair activity through inhibition of E2F transcriptional activity. Nat Cell Biol 7, 137-47
15619620   Curated Info

133

Chadee DN, Kyriakis JM (2004) MLK3 is required for mitogen activation of B-Raf, ERK and cell proliferation. Nat Cell Biol 6, 770-6
15258589   Curated Info

134

Gao N, et al. (2004) G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol 287, C281-91
15028555   Curated Info

135

Hashimoto T, et al. (2004) Caffeine inhibits cell proliferation by G0/G1 phase arrest in JB6 cells. Cancer Res 64, 3344-9
15126379   Curated Info

136

Ren S, Rollins BJ (2004) Cyclin C/cdk3 promotes Rb-dependent G0 exit. Cell 117, 239-51
15084261   Curated Info

137

Gao N, Zhang Z, Jiang BH, Shi X (2003) Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun 310, 1124-32
14559232   Curated Info

138

Joerges C, Kuntze I, Herzinger T, Herzinge T (2003) Induction of a caffeine-sensitive S-phase cell cycle checkpoint by psoralen plus ultraviolet A radiation. Oncogene 22, 6119-28
13679850   Curated Info

139

Dimberg A, Karlberg I, Nilsson K, Oberg F (2003) Ser727/Tyr701-phosphorylated Stat1 is required for the regulation of c-Myc, cyclins, and p27Kip1 associated with ATRA-induced G0/G1 arrest of U-937 cells. Blood 102, 254-61
12637327   Curated Info

140

Balasenthil S, Vadlamudi RK (2003) Functional interactions between the estrogen receptor coactivator PELP1/MNAR and retinoblastoma protein. J Biol Chem 278, 22119-27
12682072   Curated Info

141

Ma D, Zhou P, Harbour JW (2003) Distinct mechanisms for regulating the tumor suppressor and antiapoptotic functions of Rb. J Biol Chem 278, 19358-66
12646568   Curated Info

142

Simone C, Bagella L, Bellan C, Giordano A (2002) Physical interaction between pRb and cdk9/cyclinT2 complex. Oncogene 21, 4158-65
12037672   Curated Info

143

Pan W, Cox S, Hoess RH, Grafström RH (2001) A cyclin D1/cyclin-dependent kinase 4 binding site within the C domain of the retinoblastoma protein. Cancer Res 61, 2885-91
11306463   Curated Info

144

Brantley MA, Harbour JW (2000) Inactivation of retinoblastoma protein in uveal melanoma by phosphorylation of sites in the COOH-terminal region. Cancer Res 60, 4320-3
10969768   Curated Info

145

Knudsen ES, Wang JY (1997) Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation. Mol Cell Biol 17, 5771-83
9315635   Curated Info

146

Knudsen ES, Wang JY (1996) Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J Biol Chem 271, 8313-20
8626527   Curated Info

147

Lees JA, et al. (1991) The retinoblastoma protein is phosphorylated on multiple sites by human cdc2. EMBO J 10, 4279-90
1756735   Curated Info

148

Agarwal C, Dhanalakshmi S, Singh RP, Agarwal R Inositol hexaphosphate inhibits growth and induces G1 arrest and apoptotic death of androgen-dependent human prostate carcinoma LNCaP cells. Neoplasia 6, 646-59
15548374   Curated Info